Financial Sense Advisors Inc. Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Financial Sense Advisors Inc. bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 21,158 shares of the medical research company’s stock, valued at approximately $5,351,000. IQVIA makes up approximately 1.8% of Financial Sense Advisors Inc.’s holdings, making the stock its 14th biggest holding.

Other hedge funds have also recently made changes to their positions in the company. Norden Group LLC bought a new position in IQVIA in the 1st quarter worth about $703,000. Allspring Global Investments Holdings LLC grew its stake in IQVIA by 3.2% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 170,451 shares of the medical research company’s stock worth $43,105,000 after acquiring an additional 5,240 shares in the last quarter. Vaughan Nelson Investment Management L.P. grew its stake in IQVIA by 12.2% in the 1st quarter. Vaughan Nelson Investment Management L.P. now owns 247,926 shares of the medical research company’s stock worth $62,697,000 after acquiring an additional 26,921 shares in the last quarter. Optas LLC bought a new position in IQVIA in the 1st quarter worth about $209,000. Finally, Fiduciary Alliance LLC bought a new position in IQVIA in the 1st quarter worth about $1,864,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on IQV shares. Robert W. Baird dropped their price objective on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating on the stock in a research note on Friday, May 3rd. Barclays decreased their target price on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, June 28th. Evercore ISI decreased their target price on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a research report on Friday, May 3rd. Truist Financial decreased their target price on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Finally, The Goldman Sachs Group started coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $257.73.

IQVIA Stock Down 0.4 %

IQV stock opened at $206.65 on Thursday. The firm has a market cap of $37.65 billion, a PE ratio of 28.23, a P/E/G ratio of 1.89 and a beta of 1.49. The company has a debt-to-equity ratio of 2.02, a quick ratio of 0.88 and a current ratio of 0.88. The firm’s fifty day moving average is $222.84 and its 200 day moving average is $229.89. IQVIA Holdings Inc. has a one year low of $167.42 and a one year high of $261.73.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The business had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. On average, research analysts forecast that IQVIA Holdings Inc. will post 10.11 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.